By Alex Morgan, Senior AI Tools Analyst
Last updated: May 08, 2026

Why a Biotech’s Secrecy on Equity Could Signal a Funding Crisis Ahead

In recent weeks, discussions surrounding a biotech company’s Series A funding round have raised alarms. The firm, reportedly, has chosen not to disclose equity offerings, a choice that is not just curious but potentially catastrophic. This lack of transparency arrives against a backdrop where a staggering 70% of startups fail to secure follow-on funding, raising questions about how secrecy could be perpetuating a culture of distrust in biotech. The implications for investor confidence and overall sector health are significant.

But why should we care? The dynamics of equity visibility are pivotal—especially now, as transparency could be the only currency left to attract floundering funds in a dwindling market. If the sector continues this obfuscation, we may witness a crisis in biotech funding as severe as that faced by the infamous Theranos.

What Is Equity Transparency?

Equity transparency refers to the practice of openly disclosing the ownership stakes and financial terms associated with investments in a startup. This is not merely a best practice; it is increasingly becoming a litmus test for trustworthiness in the biotech field. Investors want to know what they’re buying into, much like a homebuyer would want a full inspection report before making a significant purchase. Currently, with a lack of clarity from many biotech firms, some investors may be stepping back before even entering the bidding war.

Why is this important? In an investment landscape where credibility can tip the balance, avoiding transparency could leave startups on shaky ground. After all, potential investors opt for companies that communicate their financial realities clearly. A refusal to disclose key terms could signal trouble ahead.

How Equity Transparency Works in Practice

To illustrate the importance of equity transparency, consider two contrasting examples in the biotech industry: Theranos and Moderna.

Theranos

The now-defunct Theranos serves as a stark warning on the dangers of secrecy. The company touted revolutionary blood-testing technology but avoided disclosing critical operational data. This culture of secrecy ultimately led to its downfall, resulting in massive investor losses and a federal indictment of founder Elizabeth Holmes. Experts estimate that investors lost nearly $900 million, demonstrating how a lack of transparency can obliterate credibility and trust.

Moderna

In sharp contrast, Moderna thrived during its Series A funding rounds, partly due to its transparent communication strategies. Early investors had clear visibility on equity stakes and a straightforward discussion about milestones and uses of funds. As a result, the company attracted more investment early on, securing a whopping $11.1 billion in revenue in 2022 from its COVID-19 vaccine alone. Moderna’s success showcases that even in a crowded marketplace, clarity can facilitate investor relationships and lead to financial triumph.

Startup Genome Report

According to a recent survey by Startup Genome, over 53% of startups that fail to disclose key financial terms face a staggering 25% lower chance of securing follow-on investments. The data is unambiguous: keeping equity details under wraps could very well diminish a startup’s chances in an already competitive space.

Common Mistakes and What to Avoid

Falling into the pitfalls of opacity can be detrimental. Here’s how top startups have failed by avoiding equity disclosures:

Mistake 1: Concealing Equity Percentages

A notable biotech startup, aiming to emulate Theranos, kept its equity percentages hidden during their fundraising phase. Investors quickly lost interest, leading the company to withdraw from potential funding entirely. The ownership stakes, kept shrouded, became a red flag for many.

Mistake 2: Ignoring Investor Sentiment

Another example features a promising healthtech startup that conducted pitches filled with jargon but failed to make key equity terms clear to potential investors. The focus on advanced tech rather than transparent discussions alienated potential stakeholders, again resulting in a failed funding round.

Mistake 3: Overemphasizing Secrecy

A recent biotech firm modeled after Theranos adopted a deliberately vague approach to its operational metrics. Investors dropped out after a series of presentations; the firm’s fear of disclosing too much data backfired completely, resulting in a noticeable decline in investor interest.

Transparency in equity negotiations isn’t just a strategic advantage; it’s unavoidable if founders are serious about courting investor confidence.

Where This Is Heading

The future of biotech funding is set to evolve dramatically. With significant drops in funding—42% in the past year alone, as reported by PitchBook—companies must adapt or find themselves outpaced by those willing to play by the rules of transparency.

We can expect two key trends in the coming year:

1. Investor Demand for Clarity: As venture capitalists like Marc Andreessen emphasize, “Transparency is not just a nicety; it’s a necessity in the investment world.” Investors will increasingly prioritize startups that demonstrate clear and straightforward equity terms during funding rounds.

2. Regulatory Impacts: New regulations around financial transparency may emerge, compelling companies to disclose more information if they wish to secure government funds or comply with investor-driven mandates. Expect more scrutiny in biotech going forward.

These trends signal a critical shift: biotech firms unable to foster open communication could find it increasingly challenging to navigate a funding environment ripe for upheaval.

FAQ

Q: What is equity transparency in startups?
A: Equity transparency involves openly disclosing ownership stakes and financial terms concerning investments in a startup. It creates trust among investors and enhances credibility in funding situations.

Q: How do I implement equity transparency in my biotech startup?
A: You can implement equity transparency by clearly communicating equity stakes and financial terms to potential investors. This includes having detailed discussions about milestones and how funds will be used during funding rounds.

Q: How does equity transparency compare to secrecy in funding?
A: Equity transparency fosters trust and attracts investors, while secrecy can deter potential backers and lead to a lack of funding. Companies like Moderna illustrate how openness can support growth compared to cases like Theranos that collapsed under secrecy.

Q: What are the costs associated with maintaining equity transparency?
A: While maintaining transparency can require investment in legal and financial advisory services, the long-term benefits of securing investor confidence often outweigh these costs. Clear disclosure can greatly improve funding success rates.

Q: What advanced strategies can enhance equity transparency?
A: Advanced strategies may include creating detailed financial reports, utilizing data analytics platforms to track metrics, and establishing clear communication channels with stakeholders to facilitate ongoing discussions about equity.

Q: What common mistakes should startups avoid regarding equity transparency?
A: Startups should avoid concealing equity percentages, using overly technical jargon, and failing to engage with investor sentiment. These mistakes can lead to diminished interest from potential funders.

Q: What is the future trend for transparency in biotech funding?
A: The trend indicates an increasing demand for transparency, driven by investor requirements and potential regulatory changes. Firms that prioritize open communication are likely to be more successful in securing funding.

Q: What is the best tool for managing financial transparency in startups?
A: One of the best tools for managing financial transparency is Amplemarket, an AI-driven sales automation platform that helps track investor leads and improve engagement throughout the funding process.

Top Tools and Solutions

To navigate this complex landscape of equity transparency, startups might consider leveraging technology for better communication and data transparency. Here are some tools that can assist:

• HighLevel — All-in-one sales funnel, CRM, and automation platform for agencies and entrepreneurs.

• Amplemarket — AI sales automation and lead generation platform.

• Trainual — Business playbook and employee training platform.

• Money Robot — Generate unlimited web 2.0 backlinks automatically. Creates spun blogs on autopilot.

• Carepatron — Healthcare practice management platform.

• Kit — Email marketing platform for creators and entrepreneurs.

Disclosure: Some links in this article may be affiliate links. We may earn a small commission at no extra cost to you. This does not influence our recommendations.